Lyfferon lyophilizate3 mln.me 5 pcs

Lyfferon has antiviral, antitumor and immunomodulatory activity.

Long-term use of the drug in individuals may cause antibodies to interferon, which leads to decreased effectiveness.

Indications

For adults as part of complex therapy:

moderate and severe forms of acute viral hepatitis B (at the beginning of the icteric period until the 5th day of jaundice; at a later date, the administration of the drug is less effective; with developing hepatic coma and cholestatic course of the disease, the drug is ineffective);
acute protracted hepatitis B and C, chronic active hepatitis B, C and D without signs of cirrhosis and when signs of liver cirrhosis appear;
viral (influenza, adenovirus, enterovirus, herpetic, mumps), viral-bacterial and mycoplasma meningoencephalitis (the use of the drug is most effective in the first 4 days of the disease);
viral conjunctivitis, keratoconjunctivitis, keratitis, keratouveitis;
stage IV kidney cancer, hairy cell leukemia, malignant lymphomas of the skin (mycosis fungoides, primary reticulosis), Kaposi’s sarcoma, basal cell and squamous cell skin cancer, keratoacanthoma, chronic myeloid leukemia, histiocytosis-X, subleukemic myelosis, essential thrombocytopenia;
multiple sclerosis.

For children as part of complex therapy:

acute lymphoblastic leukemia in the period of remission after the end of inductive chemotherapy (for 4-5 months of remission);
juvenile respiratory papillomatosis of the larynx, starting the next day after removal of papillomas.

Pharmacological effect

Laifferon has antiviral, antitumor and immunomodulatory activity.

Long-term use of the drug in individuals may cause the development of antibodies to interferon, which leads to decreased effectiveness.

Special instructions

With laryngeal papillomatosis, complete or partial remission can be obtained, but the use of the drug is recommended preferably to prevent relapses with preliminary surgical removal of the tumor.

For genital warts and plantar warts, complete clinical and histological effectiveness was obtained in 60% of cases. In subacute hepatitis, intraperitoneal and intramuscular administration significantly increases the likelihood of survival.

In acute hepatitis type B, the use of the drug is recommended if the concentration of bilirubin or the activity of “liver” enzymes remains high 4 weeks after the onset of the disease; if the test for the surface antigen of the hepatitis B virus is positive 5 weeks after the onset of the disease; if risk factors such as immunodeficiency, taking immunosuppressive drugs due to a concomitant disease, intense physical activity or taking ethanol in the prodromal or initial period of the disease appear.

The use of the drug for the treatment of adults with active chronic hepatitis B with a positive test for hepatitis B virus surface antigen resulted in 50% seroconversion 6 months after a 4-month treatment regimen. When treating children with the drug, 40% seroconversion to the surface antigen of the hepatitis B virus was obtained 6 months after the start of treatment. Particularly effective in immunosuppressed patients with chronic active hepatitis B.

In chronic hepatitis C, the use of the drug normalizes serum ALT activity in 50% of cases, although half of them experience a relapse of the disease after stopping treatment. The use of the drug for herpes zoster reduces the treatment time from 7-10 days to 3-4 days. The disappearance of pain usually occurs after 2-3 days (instead of 5-7 days).

The use of the drug prevents the development of postherpetic neuritis. After long-term treatment of asymptomatic carriers of HIV infection (3-52 months) with 3 million IU 3 times a week intramuscularly, a delay in the onset of symptoms associated with AIDS was observed by 40 months.

In this group of patients, the incubation period of the disease was extended by 50 months; There were fewer comorbidities and complications, and there was no significant decrease in the absolute number or percentage of CD4+ lymphocytes.

Early use of interferon alfa, within the first 72 hours after the onset of dengue viral fever, can prevent the occurrence of severe hemorrhagic complications and shock. The drug causes significant clinical regression or disease stabilization in hairy cell leukemia, even if the patient has previously undergone splenectomy.

In chronic myeloid leukemia, remission can be achieved with interferon monotherapy, however, since the drug gives a slower effect than cytostatics, its use is recommended to maintain remission previously achieved through chemotherapy.

The use of the drug prevents relapses for a year or more, prolongs life and significantly reduces the ratio of cells positive for the Philadelphia chromosome. When treating patients with non-Hodgkin’s lymphoma, it is recommended to use the drug after obtaining remission with chemotherapy and radiation therapy, which significantly reduces the frequency of relapses and increases survival time.

The drug should be used immediately after dissolution. Adding water should be done carefully along the wall of the vessel, avoiding the formation of foam. Do not use the drug if, after dissolution, sediment, turbidity or discoloration appears in it.

Although the drug has not been proven to have a direct cardiotoxic effect, it is possible that side effects such as fever, chills, and malaise may lead to an exacerbation of cardiovascular disease. The use of various alpha interferons is associated with an increased risk of developing allergic or autoimmune manifestations such as bronchospasm, drug-induced lupus, psoriasis, atopic dermatitis, or thyroiditis.

Although these phenomena occurred extremely rarely, the drug should be used with caution if the patient has a history of these diseases. Adverse reactions caused by taking the drug are reversible. If they occur, it is advisable to reduce the dose or interrupt treatment and take appropriate measures in accordance with the patient’s condition.

Despite the fact that side effects decrease during treatment with the drug, if they persist or reappear, the patient must be carefully monitored. Tests conducted did not reveal any teratogenicity or effects on fertility.

Studies of the effectiveness and safety of use during pregnancy have not been conducted. Taking this into account, the doctor should conduct a risk-benefit analysis of the drug in each specific case before prescribing it. used in children with viral hepatitis B, laryngeal papillomatosis, as well as benign and malignant tumors.

Side effects were similar to those seen in adults and consisted mainly of increased body temperature and general malaise. No growth disturbances or psychosomatic development were noted even after many months of continuous treatment with the drug.

Active ingredient

Interferon alpha-2b

Composition

1 ampoule contains:

Active substance:

interferon alpha-2b human recombinant 3 million IU;

Excipients:

sodium chloride,

sodium hydrogen phosphate dodecahydrate,

sodium dihydrogen phosphate dihydrate,

D-sorbitol,

urea,

rheopolyglucin.

Pregnancy

The drug is contraindicated during pregnancy.

Contraindications

severe forms of allergic diseases;
pregnancy.

Side Effects

From the body as a whole: with parenteral administration, chills, fever, fatigue, headache, malaise, and flu-like syndrome are possible. These side effects are partially relieved by paracetamol.

On the part of the organ of vision: when applied topically, conjunctival infection, hyperemia of the mucous membrane of the eye, single follicles, and swelling of the conjunctiva of the lower fornix are possible.

From laboratory parameters: leukopenia, lymphopenia, thrombocytopenia, increased activity of ALT, alkaline phosphatase. To timely detect these deviations during therapy, general clinical blood tests must be repeated every 2 weeks, and biochemical tests – every 4 weeks. In general, these changes are usually minor, asymptomatic and reversible.

In case of severe adverse reactions or their persistence for a long time, a temporary dose reduction is allowed (if the platelet count decreases to less than 50,000/μl, the absolute neutrophil count less than 750/μl) or interruption of treatment (if the platelet count decreases to less than 25,000/μl, the absolute neutrophil count less than 500/μl).

Interaction

With simultaneous use, interferon alfa-2b can reduce the activity of microsomal liver enzymes of the cytochrome P450 system and, therefore, affect the metabolism of cimetidine, phenytoin, dipyridamole, theophylline, diazepam, propranolol, warfarin, and some cytostatics.

The drug may enhance the neurotoxic, myelotoxic or cardiotoxic effects of drugs prescribed previously or simultaneously.

Storage conditions

The drug should be stored in a place protected from light and out of reach of children at a temperature of 2° to 8°C.

Shelf life

3 years

Manufacturer

Vector-Medica JSC, Russia